Thomas Powles, MD, PhD, on Metastatic Urothelial Cancer: Durvalumab Plus Targeted Treatments
ESMO 2019 CongressThomas Powles, MD, PhD, of Queen Mary University of London, discusses the first study to examine immunotherapy and targeted treatment combinations with a personalized approach in bladder cancer. FGF, TORC1/2, and PARP inhibitors were explored in combination with durvalumab in selected patients (Abstract 902O).
Related Videos
Nicoletta Colombo, MD, on Lenvatinib/Pembrolizumab for Advanced Endometrial Cancer
Nicoletta Colombo, MD, of Istituto Europeo di Oncologia, discusses the efficacy of lenvatinib/pembrolizumab in metastatic endometrial cancer. The combination showed antitumor...
Aleix Prat, MD, PhD, on a HER2-Positive Breast Cancer Biomarker: Results From the PAM50 Trial
Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyon...
Nicholas D. James, PhD, MBBS, on Prostate Cancer: STAMPEDE Trial M1|RT Comparison of Radiotherapy
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses the efficacy of prostate radiotherapy plus androgen-deprivation therapy with or without ...
Suresh S. Ramalingam, MD, on Osimertinib vs Comparator EGFR TKI in EGFR-Mutated NSCLC: The FLAURA Trial
Suresh S. Ramalingam, MD, of Emory University, discusses results from the final overall survival analysis of the phase III FLAURA trial in EGFR-mutated advanced non–...
Nicholas D. James, PhD, MBBS, on the STAMPEDE Trial: Long-Term Subgroup Analysis by Metastatic Burden in Hormone-Naive Prostate Cancer
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses results from a long-term follow-up of a cohort treated with docetaxel in the STAMPEDE ra...
